326 related articles for article (PubMed ID: 23104224)
1. Epigenetic progression of columnar cell lesions of the breast to invasive breast cancer.
Verschuur-Maes AH; de Bruin PC; van Diest PJ
Breast Cancer Res Treat; 2012 Dec; 136(3):705-15. PubMed ID: 23104224
[TBL] [Abstract][Full Text] [Related]
2. Analysis of gene copy number alterations by multiplex ligation-dependent probe amplification in columnar cell lesions of the breast.
Verschuur-Maes AH; Moelans CB; de Bruin PC; van Diest PJ
Cell Oncol (Dordr); 2014 Apr; 37(2):147-54. PubMed ID: 24692099
[TBL] [Abstract][Full Text] [Related]
3. Quantitative assessment of promoter hypermethylation during breast cancer development.
Lehmann U; Länger F; Feist H; Glöckner S; Hasemeier B; Kreipe H
Am J Pathol; 2002 Feb; 160(2):605-12. PubMed ID: 11839581
[TBL] [Abstract][Full Text] [Related]
4. Frequent promoter hypermethylation of BRCA2, CDH13, MSH6, PAX5, PAX6 and WT1 in ductal carcinoma in situ and invasive breast cancer.
Moelans CB; Verschuur-Maes AH; van Diest PJ
J Pathol; 2011 Oct; 225(2):222-31. PubMed ID: 21710692
[TBL] [Abstract][Full Text] [Related]
5. Progression risk of columnar cell lesions of the breast diagnosed in core needle biopsies.
Verschuur-Maes AH; Witkamp AJ; de Bruin PC; van der Wall E; van Diest PJ
Int J Cancer; 2011 Dec; 129(11):2674-80. PubMed ID: 21225627
[TBL] [Abstract][Full Text] [Related]
6. Tumor suppressor gene promoter hypermethylation in serum of breast cancer patients.
Dulaimi E; Hillinck J; Ibanez de Caceres I; Al-Saleem T; Cairns P
Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6189-93. PubMed ID: 15448006
[TBL] [Abstract][Full Text] [Related]
7. Promoter hypermethylation in ductal carcinoma in situ of the male breast.
Vermeulen MA; van Deurzen CHM; Doebar SC; de Leng WWJ; Martens JWM; van Diest PJ; Moelans CB
Endocr Relat Cancer; 2019 Jun; 26(6):575-584. PubMed ID: 30921768
[TBL] [Abstract][Full Text] [Related]
8. HIN-1, a putative cytokine highly expressed in normal but not cancerous mammary epithelial cells.
Krop IE; Sgroi D; Porter DA; Lunetta KL; LeVangie R; Seth P; Kaelin CM; Rhei E; Bosenberg M; Schnitt S; Marks JR; Pagon Z; Belina D; Razumovic J; Polyak K
Proc Natl Acad Sci U S A; 2001 Aug; 98(17):9796-801. PubMed ID: 11481438
[TBL] [Abstract][Full Text] [Related]
9. Lack of RUNX3 inactivation in columnar cell lesions of breast.
Subramaniam MM; Chan JY; Omar MF; Ito K; Ito Y; Yeoh KG; Salto-Tellez M; Putti TC
Histopathology; 2010 Oct; 57(4):555-63. PubMed ID: 20955380
[TBL] [Abstract][Full Text] [Related]
10. S100A7 (psoriasin) expression is associated with aggressive features and alteration of Jab1 in ductal carcinoma in situ of the breast.
Emberley ED; Alowami S; Snell L; Murphy LC; Watson PH
Breast Cancer Res; 2004; 6(4):R308-15. PubMed ID: 15217497
[TBL] [Abstract][Full Text] [Related]
11. Detection of RASSF1A aberrant promoter hypermethylation in sputum from chronic smokers and ductal carcinoma in situ from breast cancer patients.
Honorio S; Agathanggelou A; Schuermann M; Pankow W; Viacava P; Maher ER; Latif F
Oncogene; 2003 Jan; 22(1):147-50. PubMed ID: 12527916
[TBL] [Abstract][Full Text] [Related]
12. Epigenetic alterations by methylation of RASSF1A and DAPK1 promoter sequences in mammary carcinoma detected in extracellular tumor DNA.
Ahmed IA; Pusch CM; Hamed T; Rashad H; Idris A; El-Fadle AA; Blin N
Cancer Genet Cytogenet; 2010 Jun; 199(2):96-100. PubMed ID: 20471512
[TBL] [Abstract][Full Text] [Related]
13. Promoter CpG island hypermethylation during breast cancer progression.
Park SY; Kwon HJ; Lee HE; Ryu HS; Kim SW; Kim JH; Kim IA; Jung N; Cho NY; Kang GH
Virchows Arch; 2011 Jan; 458(1):73-84. PubMed ID: 21120523
[TBL] [Abstract][Full Text] [Related]
14. Id4 messenger RNA and estrogen receptor expression: inverse correlation in human normal breast epithelium and carcinoma.
de Candia P; Akram M; Benezra R; Brogi E
Hum Pathol; 2006 Aug; 37(8):1032-41. PubMed ID: 16867866
[TBL] [Abstract][Full Text] [Related]
15. Loss of the expression of the tumor suppressor gene ARHI is associated with progression of breast cancer.
Wang L; Hoque A; Luo RZ; Yuan J; Lu Z; Nishimoto A; Liu J; Sahin AA; Lippman SM; Bast RC; Yu Y
Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3660-6. PubMed ID: 14506155
[TBL] [Abstract][Full Text] [Related]
16. RASSF1A and CDH1 hypermethylation as potential epimarkers in breast cancer.
Sebova K; Zmetakova I; Bella V; Kajo K; Stankovicova I; Kajabova V; Krivulcik T; Lasabova Z; Tomka M; Galbavy S; Fridrichova I
Cancer Biomark; 2011-2012; 10(1):13-26. PubMed ID: 22297548
[TBL] [Abstract][Full Text] [Related]
17. RUNX3 inactivation by frequent promoter hypermethylation and protein mislocalization constitute an early event in breast cancer progression.
Subramaniam MM; Chan JY; Soong R; Ito K; Ito Y; Yeoh KG; Salto-Tellez M; Putti TC
Breast Cancer Res Treat; 2009 Jan; 113(1):113-21. PubMed ID: 18256927
[TBL] [Abstract][Full Text] [Related]
18. Promoter hypermethylation profile of ovarian epithelial neoplasms.
Makarla PB; Saboorian MH; Ashfaq R; Toyooka KO; Toyooka S; Minna JD; Gazdar AF; Schorge JO
Clin Cancer Res; 2005 Aug; 11(15):5365-9. PubMed ID: 16061849
[TBL] [Abstract][Full Text] [Related]
19. Genetic clonal mapping of in situ and invasive ductal carcinoma indicates the field cancerization phenomenon in the breast.
Foschini MP; Morandi L; Leonardi E; Flamminio F; Ishikawa Y; Masetti R; Eusebi V
Hum Pathol; 2013 Jul; 44(7):1310-9. PubMed ID: 23337025
[TBL] [Abstract][Full Text] [Related]
20. Clinical significance of promoter hypermethylation of DNA repair genes in tumor and serum DNA in invasive ductal breast carcinoma patients.
Sharma G; Mirza S; Parshad R; Srivastava A; Gupta SD; Pandya P; Ralhan R
Life Sci; 2010 Jul; 87(3-4):83-91. PubMed ID: 20470789
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]